Signalling pathways involved in sildenafil‐induced relaxation of human bladder dome smooth muscle
暂无分享,去创建一个
P. Validire | T. Lebret | S. Oger | D. Behr-Roussel | D. Gorny | L. Alexandre | F. Giuliano | X. Cathelineau
[1] H. Uemura,et al. Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats , 2010, International Urology and Nephrology.
[2] K. Andersson,et al. Vardenafil‐induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder , 2009, BJU international.
[3] M. Carini,et al. Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. , 2009, The journal of sexual medicine.
[4] T. Lebret,et al. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. , 2009, The journal of sexual medicine.
[5] C. Roehrborn,et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. , 2008, The Journal of urology.
[6] C. Roehrborn,et al. Lower urinary tract symptoms revisited: a broader clinical perspective. , 2008, European urology.
[7] C. Stief,et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2008, European urology.
[8] F. Giuliano. Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms. , 2008, European urology.
[9] K. Kohri,et al. Role of nitric oxide/cyclic GMP pathway in regulating spontaneous excitations in detrusor smooth muscle of the guinea‐pig bladder , 2008, Neurourology and urodynamics.
[10] S. Oger,et al. PDE5 GENE EXPRESSION AND RELAXANT EFFECTS OF VARDENAFIL IN MALE AND FEMALE HUMAN AND RAT DETRUSOR MUSCLE , 2008 .
[11] J A Peters,et al. Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.
[12] R. B. de Oliveira,et al. Sildenafil inhibits duodenal contractility via activation of the NO–K+ channel pathway , 2008, Fundamental & clinical pharmacology.
[13] J. Medeiros,et al. Role of the NO/cGMP/KATP pathway in the protective effects of sildenafil against ethanol‐induced gastric damage in rats , 2008, British journal of pharmacology.
[14] C. Roehrborn,et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2007, The Journal of urology.
[15] M. Carini,et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. , 2007, The Journal of urology.
[16] M. Carini,et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. , 2007, Endocrinology.
[17] T. Lebret,et al. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition. , 2007, European urology.
[18] K. McVary,et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. , 2007, The Journal of urology.
[19] P. Sandner,et al. Pre‐clinical evidence for the use of phosphodiesterase‐5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms , 2006, BJU international.
[20] L. Rivera,et al. Role of nitric oxide in the relaxation elicited by sildenafil in penile resistance arteries. , 2006, The Journal of urology.
[21] N. Villalba,et al. Ca2+-activated K+ (KCa) channels are involved in the relaxations elicited by sildenafil in penile resistance arteries. , 2006, European journal of pharmacology.
[22] G. Christ,et al. Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction , 2006, British journal of pharmacology.
[23] P. Hedlund. Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract—is there a basis for pharmacological targeting of cGMP? , 2005, World Journal of Urology.
[24] S. Archer,et al. The neurovascular mechanism of clitoral erection: nitric oxide and cGMP‐stimulated activation of BKCa channels , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] J. Corbin,et al. Mechanisms of action of PDE5 inhibition in erectile dysfunction , 2004, International Journal of Impotence Research.
[26] E. Bischoff. Potency, selectivity, and consequences of nonselectivity of PDE inhibition , 2004, International Journal of Impotence Research.
[27] P. Boyle,et al. [Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging.male (MSAM-7)]. , 2003, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[28] C. Stief,et al. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle , 1996, Urological Research.
[29] J. Reynard,et al. Nitric oxide and the lower urinary tract: current concepts, future prospects. , 2003, Urology.
[30] H. Kilbinger,et al. Inhibition of human detrusor contraction by a urothelium derived factor. , 2003, The Journal of urology.
[31] S. Hourani,et al. Sodium nitroprusside-induced rat fundus relaxation is ryanodine-sensitive and involves L-type Ca2+ channel and small conductance Ca(2+)-sensitive K+ channel components. , 2002, Autonomic & autacoid pharmacology.
[32] D. Webb,et al. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. , 2002, Urology.
[33] A. Moon. Influence of nitric oxide signalling pathways on pre‐contracted human detrusor smooth muscle in vitro , 2002, BJU international.
[34] S. Lee,et al. Effects of nitric oxide on the Ca2+-activated potassium channels in smooth muscle cells of the human corpus cavernosum , 2001, Urological Research.
[35] C. Stief,et al. Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder , 2000, World Journal of Urology.
[36] U. Jonas,et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. , 2000, Urology.
[37] G. Angelini,et al. Prostaglandins and cyclic nucleotides in the urinary bladder of a rabbit model of partial bladder outlet obstruction. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.
[38] A. Kanai,et al. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. , 1998, American journal of physiology. Renal physiology.
[39] C. Stief,et al. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. , 1998, Urological research.
[40] K. Andersson,et al. Nitric oxide and relaxation of pig lower urinary tract , 1992, British journal of pharmacology.
[41] R. Paoletti,et al. Prostaglandins and Cyclic Nucleotides , 1982 .